Publications by authors named "Danielle da Nóbrega Alves"

4 Publications

  • Page 1 of 1

Toxicological Parameters of a Formulation Containing Cinnamaldehyde for Use in Treatment of Oral Fungal Infections: An Study.

Biomed Res Int 2021 22;2021:2305695. Epub 2021 Oct 22.

Department of Clinical and Social Dentistry, Center for Health Sciences, Federal University of Paraiba, João Pessoa PB, Brazil.

Objective: We aimed to define the safety and toxicity of both isolated and embedded cinnamaldehyde using a pharmaceutical formulation for the treatment of oral fungal infections in an study.

Materials And Methods: Acute toxicity was assessed in studies with larvae and embryos (zebrafish), and genotoxicity was assessed in a mouse model. The pharmaceutical formulation (orabase ointment) containing cinnamaldehyde was evaluated for verification of both antifungal activity and toxicity in keratinized oral rat mucosa.

Results: In larvae, cinnamaldehyde was not toxic up to the highest dose tested (20 mg/kg) and presented no genotoxicity up to the dose of 4 mg/kg in the model using mice. However, it was found to be toxic in zebrafish embryos up to a concentration of 0.035 g/mL; LC 0.311; EC 0.097 (egg hatching delay); and 0.105 (Pericardial edema). In the orabase antifungal susceptibility test, cinnamaldehyde exhibited activity in concentrations greater than 200 g/mL. As for safety in the animal model with rats, the orabase ointment proved to be safe for use on keratinized mucosa up to the maximum concentration tested (700 g/mL).

Conclusions: At the concentrations tested, cinnamaldehyde was not toxic in vertebrate and invertebrate animal models and did not exhibit genotoxic activity. In addition, when used in the form of an ointment in orabase, having already recognized antifungal activity, it was shown to be safe up to the highest concentration tested.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1155/2021/2305695DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556081PMC
October 2021

Breakpoints for the Classification of Anti- Compounds in Antifungal Screening.

Biomed Res Int 2021 6;2021:6653311. Epub 2021 Apr 6.

Department of Clinic and Social Dentistry, Graduate Program in Natural and Synthetic Bioactive Products (PgPNSB), Center for Health Sciences, Federal University of Paraiba, João Pessoa, PB, Brazil.

Introduction: The absence of a standardized classification scheme for the antifungal potency of compounds screened against species may hinder the study of new drugs. This systematic review proposes a scheme of interpretative breakpoints for the minimum inhibitory concentration (MIC) of bioactive compounds against species in tests.

Materials And Methods: A literature search was conducted in the PubMed, Scopus, Web of Science, Lilacs, and SciFinder databases for the period from January 2015 to April 2020. The following inclusion criterion was used: organic compounds tested by the microdilution technique according to the Clinical and Laboratory Standards Institute protocol against reference strains of the genus . A total of 545 articles were retrieved after removing duplicates. Of these, 106 articles were selected after applying the exclusion criteria and were evaluated according to the number of synthesized molecules and their chemical classes, the type of strain (reference or clinical) used in the antifungal test, the species, and the MIC (in g/mL) used.

Results: The analysis was performed based on the median, quartiles (25% and 75%), maximum, and minimum values of four groups: all strains, ATCC strains, strains, and ATCC strains. The following breakpoints were proposed to define the categories: MIC < 3.515 g/mL (very strong bioactivity); 3.516-25 g/mL (strong bioactivity); 26-100 g/mL (moderate bioactivity); 101-500 g/mL (weak bioactivity); 500-2000 g/mL (very weak bioactivity); and >2000 g/mL (no bioactivity).

Conclusions: A classification scheme of the antifungal potency of compounds against species is proposed that can be used to identify the antifungal potential of new drug candidates.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1155/2021/6653311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046529PMC
May 2021

Efficacy of essential oil of cinnamon for the treatment of oral candidiasis: A randomized trial.

Spec Care Dentist 2021 May 21;41(3):349-357. Epub 2021 Jan 21.

Departament of Clinical and Social Dentistry, Federal University of Paraíba, João Pessoa, Brazil.

Aim: It was analyzed the efficacy of mouthwash and spray containing essential oil (EO) of Cinnamomum zeylanicum Blume for the treatment of oral candidiasis.

Methods And Results: A randomized, controlled, and blinded clinical trial was conducted with 36 individuals (probabilistic sample) with oral candidiasis who were divided into two treatment groups: C. zeylanicum (0.5 mg/mL), n = 18; nystatin (100,000IU/mL), n = 18. The efficacy of the products was evaluated by two parameters: (a) clinical evolution recorded by calibrated examiners (Kappa = 0.822) according to Newton's classification and (b) reduction of colony-forming units/mL. Mycological and clinical parameters were analyzed before and at 15 days after treatment. Clinical examination of the mucosa showed that C. zeylanicum (p < 0.0339) and nystatin (p < .0139) had efficacy, resulting in a reduction of signs and symptoms (Mann-Whitney test). Mycological analysis showed that C. zeylanicum caused a reduction of 61% and 33% of Candida spp., isolates oral mucosa and dentures, respectively. Candida tropicalis strains were eliminated after C. zeylanicum, in both sites. The participants reported a pleasant taste and few product-related complaints.

Conclusion: C. zeylanicum EO and nystatin exhibited clinical efficacy, according to the Newton classification, and reducing in Candida spp. The clinical trial has been registered (Registration number: NBR-33s6 × 5, ensaiosclinicos.gov.br).
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/scd.12570DOI Listing
May 2021

Docking Prediction, Antifungal Activity, Anti-Biofilm Effects on spp., and Toxicity against Human Cells of Cinnamaldehyde.

Molecules 2020 Dec 16;25(24). Epub 2020 Dec 16.

Department of Clinic and Social Dentistry, Center for Health Sciences, Federal University of Paraiba, João Pessoa-PB 58051-900, Brazil.

Objective: This study evaluated the antifungal activity of cinnamaldehyde on spp. In vitro and in situ assays were carried out to test cinnamaldehyde for its anti- effects, antibiofilm activity, effects on fungal micromorphology, antioxidant activity, and toxicity on keratinocytes and human erythrocytes. Statistical analysis was performed considering α = 5%.

Results: The minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of cinnamaldehyde ranged from 18.91 μM to 37.83 μM. MIC values did not change in the presence of 0.8 M sorbitol, whereas an 8-fold increase was observed in the presence of ergosterol, suggesting that cinnamaldehyde may act on the cell membrane, which was subsequently confirmed by docking analysis. The action of cinnamaldehyde likely includes binding to enzymes involved in the formation of the cytoplasmic membrane in yeast cells. Cinnamaldehyde-treated microcultures showed impaired cellular development, with an expression of rare pseudo-hyphae and absence of chlamydoconidia. Cinnamaldehyde reduced biofilm adherence by 64.52% to 33.75% ( < 0.0001) at low concentrations (378.3-151.3 µM). Cinnamaldehyde did not show antioxidant properties.

Conclusions: Cinnamaldehyde showed fungicidal activity through a mechanism of action likely related to ergosterol complexation; it was non-cytotoxic to keratinocytes and human erythrocytes and showed no antioxidant activity.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules25245969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767272PMC
December 2020
-->